Vium develops a living informatics platform for preclinical in vivo drug research, centering on its Vium Digital VivariumTM, Vium Cloud, and online Research Suite. The platform enables scientists to optimize bioengineered research models and accelerate preclinical drug discovery and development. Customers include biotechnology, pharmaceutical and computational drug discovery companies, academia, and novel therapeutic labs. The company is led by President and CEO Wendel Barr and is based in San Mateo, California. Vium's solution is fully accredited by AAALAC International. Vium closed a $24M Series B financing in June 2018.

Total raised

$24M

Funding rounds

1

Latest round

Series B

Latest activity

Jun 2018